AB Science

AB Science was founded in 2001 by a team of researchers, clinicians and entrepreneurs who have dedicated their lives to discover key mechanisms in life science and develop new drugs targeting these mechanisms to dramatically change the life of patients in the most unmet medical needs. We are innovators and scientific entrepreneurs in the field of life science. Our group is specialized in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical needs in the field of cancers, chronic inflammatory diseases and neurological degenerative disorders. We remain fully committed in meeting our objectives and we are very confident in our capacities to develop leading treatments that will dramatically change the lives of the patients.
Type
Public
HQ
Paris, FR
Founded
2001
Size (employees)
136 (est)-6%
AB Science was founded in 2001 and is headquartered in Paris, FR

AB Science Office Locations

AB Science has offices in Paris and Chatham
Paris, FR (HQ)
3 Avenue George V
Chatham, US
39 Main St

AB Science Data and Metrics

AB Science Financial Metrics

EUR

Market capitalization (24-Jul-2017)

383.8 m

Closing share price (24-Jul-2017)

10
AB Science's current market capitalization is €383.8 m.

AB Science Market Value History

Traffic Overview of AB Science

AB Science News and Updates

The FDA just approved the first new drug to treat ALS in 22 years (AB)

May 5 (Reuters) -The FDA just approved a new drug for ALS. It's the first new drug to treat the neurodegenerative disease to get US approval in 22 years. The drug, known chemically as edaravone, is already sold by Japanese pharmaceutical company Mitsubishi Tanabe Pharma Corp…

AB Science Company Life and Culture

You may also be interested in